Alterity Therapeutics Ltd (ATHE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $37.42M
Last updated: Nov 17, 2026 at 10:57 AM ET
Alterity Therapeutics Ltd (ATHE) Financials: Revenue, Profit and Cash Flow
Alterity Therapeutics reported revenue of AUD 0 for the fiscal year ended Jun 30, 2026, down 100.0% from the year before. That year, net income was AUD -22.89M, operating cash flow was AUD -22.03M and free cash flow was AUD -44.06M. The quarter ended Jun 30, 2026 had net income of AUD -13.98M.
Revenue and Margins
The company reported no revenue in the fiscal year ended Jun 2026, with an operating loss of AUD 27.80M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Jun 2026 | 0 | -100.0% | N/A | N/A | N/A |
| Jun 2025 | 5.44M | +35.3% | 97.7% | -268.0% | -223.4% |
| Jun 2024 | 4.02M | +2.6% | 94.7% | -487.7% | -475.8% |
| Jun 2023 | 3.92M | -23.6% | 92.7% | -373.7% | -352.5% |
| Jun 2022 | 5.12M | +18.1% | 92.9% | -302.6% | -250.7% |
| Jun 2021 | 4.34M | +954.4% | 91.7% | -349.8% | -352.8% |
| Jun 2020 | 411.57K | +279.2% | -27.3% | -2530.3% | -2444.2% |
| Jun 2019 | 108.54K | -46.0% | 72.6% | -11713.7% | -11020.8% |
| Jun 2018 | 201.17K | +51.9% | 89.2% | -3862.5% | -4108.8% |
| Jun 2017 | 132.40K | N/A | 83.9% | -5197.9% | -5696.6% |
Income Statement
In the fiscal year ended Jun 2026, the net loss widened from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 5.44M | 4.02M | 3.92M | 5.12M | 4.34M | 411.57K | 108.54K | 201.17K | 132.40K |
| Cost of revenue | 113.01K | 127.52K | 214.30K | 285.07K | 364.67K | 360.03K | 112.43K | 29.70K | 21.80K | 21.33K |
| Gross profit | -113.01K | 5.31M | 3.80M | 3.63M | 4.76M | 3.98M | -112.43K | 78.84K | 179.38K | 111.07K |
| Research and development | 17.24M | 14.40M | 18.64M | 13.20M | 14.75M | 12.28M | 10.10M | 12.98M | 6.70M | 5.70M |
| Operating income | -27.80M | -14.57M | -19.60M | -14.64M | -15.50M | -15.18M | -10.41M | -12.71M | -7.77M | -6.88M |
| Net income | -22.89M | -12.15M | -19.12M | -13.81M | -12.85M | -15.31M | -10.06M | -11.96M | -8.27M | -7.54M |
| EBITDA | -27.69M | -14.52M | -19.46M | -14.53M | N/A | -15.10M | N/A | N/A | N/A | -6.86M |
Quarterly
| Line item | Jun 2026 | Dec 2025 | Jun 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | 3.83M | 1.61M | 802.96K | 2.12M | 1.06M | 1.90M | 950.36K | 1.53M | 765.25K | 2.39M |
| Gross profit | -58.46K | -56.83K | 3.77M | 1.54M | 771.16K | 2.04M | 1.00M | 1.83M | 901.88K | 1.48M | 702.73K | 2.34M |
| Operating income | -15.58M | -12.82M | -7.09M | -7.49M | -3.74M | -12.98M | -6.49M | -4.50M | -3.31M | -7.77M | -3.12M | -10.75M |
| Net income | -13.98M | -9.44M | -4.97M | -7.17M | -3.59M | -12.62M | -6.31M | -6.51M | -3.25M | -5.77M | -2.89M | -8.03M |
Balance Sheet
As of Jun 2026, cash and equivalents exceeded short-term debt of AUD 55.18K by 37.26M.
Annual
| Line item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 46.02M | 46.03M | 19.22M | 27.32M | 41.36M | 33.59M | 13.30M | 19.91M | 18.73M | 25.28M |
| Current assets | 45.83M | 45.87M | 19.04M | 27.05M | 41.14M | 33.49M | 13.23M | 19.86M | 18.65M | 25.25M |
| Cash and equivalents | 37.32M | 33.16M | 12.64M | 15.77M | 34.81M | 28.12M | 9.20M | 14.40M | 15.24M | 21.88M |
| Total liabilities | 3.29M | 3.62M | 5.43M | 4.50M | 5.89M | 3.12M | 2.76M | 3.36M | 2.64M | 1.59M |
| Short-term debt | 55.18K | 66.91K | 107.13K | 107.18K | 57.63K | 27.75K | 32.88K | 0 | 0 | 0 |
| Shareholder equity | 42.73M | 42.40M | 13.80M | 22.81M | 35.47M | 30.47M | 10.55M | 16.55M | 16.08M | 23.69M |
Quarterly
| Line item | Jun 2026 | Dec 2025 | Jun 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 46.02M | 56.86M | 46.03M | 10.55M | 10.55M | 19.22M | 19.22M | 22.19M | 22.19M | 27.32M | 27.32M | 33.38M |
| Total liabilities | 3.29M | 2.65M | 3.62M | 2.76M | 2.76M | 5.43M | 5.43M | 4.57M | 4.57M | 4.50M | 4.50M | 5.28M |
| Cash and equivalents | 37.32M | 49.15M | 33.16M | 4.54M | 4.54M | 12.64M | 12.64M | 12.32M | 12.32M | 15.77M | 15.77M | 25.34M |
| Shareholder equity | 42.73M | 54.21M | 42.40M | 7.79M | 7.79M | 13.80M | 13.80M | 17.62M | 17.62M | 22.81M | 22.81M | 28.10M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Jun 2026.
Annual
| Line item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -22.03M | -11.45M | -12.61M | -20.04M | -12.34M | -17.33M | -9.43M | -13.95M | -6.25M | -5.87M |
| Capital expenditures | 22.03M | 3 | 5.72K | 7.31K | 89.15K | 10.47K | 16.74K | 7.02K | 62.41K | 27.92K |
| Free cash flow | -44.06M | -11.45M | -12.61M | -20.04M | -12.43M | -17.34M | -9.45M | -13.96M | -6.31M | -5.89M |
| Investing cash flow | 7.34M | -7.50M | -5.72K | -36.46K | -89.15K | -10.47K | -16.74K | -7.02K | -18.42K | -27.92K |
| Financing cash flow | 18.71M | 39.67M | 9.22M | 124.34K | 16.30M | 36.69M | 3.98M | 12.72M | -107.68K | -159.56K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -1.34M | -12.80M | N/A | -10.43M | -2.36M | N/A | -8.36M | -4.18M | -8.11M | N/A | -4.49M | 549.00K |
| Capital expenditures | 8.00K | 12.80M | 0 | 10.43M | 0 | 0 | 2 | 0 | 278 | 0 | 2.00K | 4.00K |
| Free cash flow | -1.35M | -25.59M | N/A | -20.85M | -2.36M | N/A | -8.36M | -4.18M | -8.11M | N/A | -4.50M | 545.00K |
Frequently Asked Questions About ATHE
What is Alterity Therapeutics' annual revenue?
Alterity Therapeutics reported revenue of AUD 0 for the fiscal year ended Jun 30, 2026.
How fast is Alterity Therapeutics' revenue growing?
Revenue was down 100.0% for the fiscal year ended Jun 30, 2026 compared with the year before.
Is Alterity Therapeutics profitable?
No. Alterity Therapeutics reported net income of AUD -22.89M for the fiscal year ended Jun 30, 2026.
How much free cash flow does ATHE generate?
For the fiscal year ended Jun 30, 2026, operating cash flow of AUD -22.03M minus capital expenditures of AUD 22.03M produced free cash flow of AUD -44.06M.
How much debt does Alterity Therapeutics have?
The balance sheet dated Jun 30, 2026 reported short-term debt of AUD 55.18K and cash and equivalents of AUD 37.32M.
ATHE pages: Overview, Financials